Recently, doctors have been reporting concerning findings regarding popular weight loss drugs, specifically GLP-1 medications like Mounjaro and Ozempic. While these medications have been shown to be helpful in aiding weight loss for patients, there is a growing concern that they may actually worsen eating disorders in some individuals.
GLP-1 medications work by increasing feelings of fullness and reducing appetite, which can lead to successful weight loss for many patients. However, for those with a history of eating disorders or disordered eating behaviors, these drugs may have unintended consequences.
Doctors have noticed that some patients taking GLP-1 medications have reported an increase in obsessive thoughts about food, body image concerns, and restrictive eating habits. This is particularly worrisome for individuals who are already vulnerable to developing or struggling with eating disorders.
It is important for healthcare providers to carefully screen patients for a history of eating disorders before prescribing GLP-1 medications for weight loss. Additionally, close monitoring and support should be provided for those at risk for developing disordered eating behaviors while taking these drugs.
While GLP-1 medications can be a valuable tool in the treatment of obesity, it is crucial to consider the potential risks and side effects, especially in vulnerable populations. By being aware of these potential complications, healthcare providers can work to minimize the negative impact on their patients’ overall well-being.
Watch the video by NBC News
Video “Popular weight loss drugs may worsen eating disorders in patients” was uploaded on 08/01/2024 to Youtube Channel NBC News